CODA Biotherapeutics, Inc., a preclinical-stage biopharmaceutical company developing a gene therapy-mediated chemogenetic platform, today announced it has completed the acquisition of Attenua, Inc. With the acquisition, CODA has obtained three small molecule drugs that have been shown to be safe and well tolerated in multiple clinical trials up to and including Phase II studies. CODA has engineered several chemogenetic receptors that can be specifically controlled by small molecule ligands, including clinical stage candidates from the Attenua portfolio. CODA plans to evaluate and advance these unique receptor-ligand pairs toward the clinic to treat neuropathic pain, focal epilepsy, and other neurologic diseases and disorders.
Read the full article: CODA Biotherapeutics Acquires Attenua //
Source: https://www.prnewswire.com/news-releases/coda-biotherapeutics-acquires-attenua-and-three-clinical-stage-assets-300999026.html